Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
PGE synthase CRISPR/Cas9 KO Plasmid (h): sc-402085
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PGE synthase CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the PGE synthase genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: PGE synthase Antibody (A-3): sc-166308
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PGE synthase CRISPR/Cas9 KO Plasmid (h) | sc-402085 | 20 µg | $397.00 |
Overview
PTGES encodes prostaglandin E synthase, a key terminal enzyme in the arachidonic acid cascade that converts COX-derived prostaglandin H2 into prostaglandin E2 (PGE2). By controlling PGE2 abundance, PTGES contributes to inflammatory signaling, pain sensitization, fever responses, and modulation of immune cell function through EP receptor pathways and downstream cAMP/PKA signaling. PTGES activity intersects with cytokine-driven programs (for example, NF-κB–linked induction) and influences processes such as vascular tone regulation and epithelial barrier responses. Dysregulated PGE2 biosynthesis and PTGES expression have been associated with chronic inflammation and tumor-associated microenvironmental signaling, supporting its relevance in mechanistic studies of inflammation-linked pathophysiology.
PGE synthase CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the PTGES gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the PTGES together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the PTGES open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish PGE synthase protein expression.
This CRISPR knockout system enables efficient generation of PTGES-deficient cell models for investigation of PGE synthase signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting PTGES exon(s) critical for PGE synthase function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple PTGES genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by PGE synthase CRISPR/Cas9 KO Plasmid (h) and PGE synthase CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the PTGES locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by PGE synthase HDR Plasmid (h) and PGE synthase HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by PTGES homology arms to support homology-directed repair at defined PTGES target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.